Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Cheryl Blanchard, President and CEO, will deliver a presentation on Thursday, January 16, 2025, at 9:45am PT / 12:45pm ET in San Francisco.
The presentation will be accessible via live webcast on the Events and Webcasts page in the Investors section of Anika's website, remaining available for 30 days afterward. The company's management team will also engage in one-on-one investor meetings throughout the event. Interested parties can arrange meetings through Anika's Investor Relations.
Anika Therapeutics (NASDAQ: ANIK), una azienda globale specializzata nella conservazione delle articolazioni e focalizzata sulla ortopedia dell'intervento precoce, ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. La Dott.ssa Cheryl Blanchard, Presidente e CEO, terrà una presentazione giovedì 16 gennaio 2025, alle 9:45 PT / 12:45 ET a San Francisco.
La presentazione sarà accessibile tramite webcast dal vivo nella pagina Eventi e Webcast della sezione Investitori del sito web di Anika, e rimarrà disponibile per 30 giorni dopo. Anche il team di gestione dell'azienda parteciperà a incontri individuali con gli investitori durante l'evento. Le parti interessate possono organizzare incontri attraverso le Relazioni con gli Investitori di Anika.
Anika Therapeutics (NASDAQ: ANIK), una empresa global especializada en la preservación de articulaciones y enfocada en ortopedia de intervención temprana, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. La Dra. Cheryl Blanchard, Presidenta y CEO, realizará una presentación el jueves 16 de enero de 2025, a las 9:45 PT / 12:45 ET en San Francisco.
La presentación estará disponible a través de un webcast en vivo en la página de Eventos y Webcasts en la sección de Inversores del sitio web de Anika, y estará disponible durante 30 días después. El equipo directivo de la empresa también participará en reuniones individuales con inversores durante el evento. Las partes interesadas pueden organizar reuniones a través de las Relaciones con Inversores de Anika.
Anika Therapeutics (NASDAQ: ANIK), 조기 개입 정형외과에 특화된 글로벌 관절 보존 회사,가 제43회 연례 J.P. Morgan 헬스케어 콘퍼런스에 참여한다고 발표했습니다. Cheryl Blanchard 박사, 사장兼 CEO가 2025년 1월 16일 목요일, 오전 9:45 PT / 오후 12:45 ET에 샌프란시스코에서 발표합니다.
이 발표는 Anika 웹사이트 투자자 섹션의 이벤트 및 웹캐스트 페이지를 통해 라이브 웹캐스트로 접근할 수 있으며, 이후 30일간 이용할 수 있습니다. 또한 회사의 경영진은 행사 기간 동안 개별 투자자 회의에 참여할 예정입니다. 관심 있는 분들은 Anika의 투자자 관계를 통해 회의를 주선할 수 있습니다.
Anika Therapeutics (NASDAQ: ANIK), une entreprise mondiale spécialisée dans la préservation des articulations et axée sur l'orthopédie d'intervention précoce, a annoncé sa participation à la 43e Conférence Annuelle de Santé J.P. Morgan. La Dre Cheryl Blanchard, Présidente et CEO, fera une présentation le jeudi 16 janvier 2025, à 9h45 PT / 12h45 ET à San Francisco.
La présentation sera accessible en direct via webcast sur la page Événements et Webcasts dans la section Investisseurs du site d'Anika, et restera disponible pendant 30 jours par la suite. L'équipe de direction de l'entreprise participera également à des réunions individuelles avec des investisseurs tout au long de l'événement. Les parties intéressées peuvent organiser des réunions par l'intermédiaire des Relations Investisseurs d'Anika.
Anika Therapeutics (NASDAQ: ANIK), ein globales Unternehmen zur Erhaltung von Gelenken, das sich auf frühzeitige Intervention in der Orthopädie spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. Dr. Cheryl Blanchard, Präsidentin und CEO, wird am Donnerstag, den 16. Januar 2025, um 9:45 Uhr PT / 12:45 Uhr ET in San Francisco eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast auf der Seite Veranstaltungen und Webcasts im Bereich Investoren auf Anikas Website zugänglich sein und bleibt anschließend 30 Tage lang verfügbar. Das Management-Team des Unternehmens wird außerdem während der Veranstaltung an persönlichen Investorengesprächen teilnehmen. Interessierte Parteien können Meetings über Anikas Investor Relations arrangieren.
- None.
- None.
BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event.
The presentation will be webcast live on the Events and Webcasts page under the Investors section of Anika Therapeutics’ website and will be archived for 30 days following the presentation. For more information about this event or to schedule a one-on-one meeting with Anika’s senior management, please contact Anika’s Investor Relations at investorrelations@anika.com.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, TACTOSET, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
When is Anika Therapeutics (ANIK) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Anika's (ANIK) J.P. Morgan Healthcare Conference presentation?
How long will Anika's (ANIK) J.P. Morgan Conference presentation recording be available?
How can investors schedule one-on-one meetings with Anika (ANIK) management at the J.P. Morgan Conference?
